Why write ten lines of code when one will do? From magic variable swaps to high-speed data counting, these Python snippets ...

Leprosy carried powerful stigma in medieval Europe, but new skeletal evidence from Danish cemeteries suggests the sick were not always pushed aside in death. In medieval Denmark, burial location ...

Women gather at a neighborhood square in Lilongwe, Malawi, on June 8 Women gather at a neighborhood square in Lilongwe, Malawi, on June 8Zafer Goder—Anadolu/Getty Images In Malawi, one in three women ...

Exclamation marks, ellipses and ‘haha’ can’t fix our growing inability to communicate. By Nitsuh Abebe “How Many Exclamation Points Are Too Many in an Email? A Psychologist Weighs In.” A psychologist!

Master AI hackathons with this comprehensive playbook on Vibe Coding. Learn how to build winning AI hackathon apps using AI ...

Still, being ghosted—when the other person disappears without explanation—can be shocking, hurtful and confusing to those being left on read. According to a new psychological analysis, the impulse to ...

(via Sabine Hossenfelder) When electricity first emerged as a technology, Edison and Tesla clashed in the “war of currents,” arguing over whether alternating current (AC) or direct current (DC) should ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...